Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Liver transcriptome regulated by CtBP2

ABSTRACT: adenovirus mediated overexpression of wild-type CtBP2 and Rossmann fold mutant CtBP2 along with control GUS in dietary induced obese mice

ORGANISM(S): Mus musculus

PROVIDER: GSE128145 | GEO | 2021/09/27

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Liver transcriptome regulated by CtBP2

Project description:Liver transcriptome regulated by CtBP2

| PRJNA526541 | ENA

CtBP2 ChIP-seq normal mouse liver

Project description:CtBP2 recruitment on genome in normal mouse liver

2021-09-27 | GSE127660 | GEO

Genome wide expression analysis of Ctbp2 knock down mouse F9 cells

Project description:Using an RNA interference-based genetic screen in mouse F9 cells we identify the transcriptional corepressor CTBP2 as a coactivator critically required for retinoic acid (RA)-induced transcription. Here we perfom a whole genome transcriptome analysis in F9 cells expressing shRNA for Ctbp2 and Rxr in the absence or presence of retinoic acid (RA). A total of 2,754 genes were found to be upregulated (>2 fold) and 1518 genes were downregulated (>2 fold) in response to RA treatment in the control cells. We find that around 52% and 55% of upregulated genes are dependent on Ctbp2 and Rxr for activation respectively suggesting that Ctbp2 is a coactivator of RA signaling. Whole genome RNA-sequencing in F9 cells expressing shGFP or shCtbp2 or shRxr

2013-06-21 | E-GEOD-47708 | biostudies-arrayexpress

Genome wide expression analysis of Ctbp2 knock down mouse F9 cells

2013-06-21 | GSE47708 | GEO

CtBP2 ChIP-seq normal mouse liver

Project description:CtBP2 ChIP-seq normal mouse liver

| PRJNA525001 | ENA

Genome-wide analysis upon ZBTB18 expression and/or CTBP2 silencing in Glioblastoma

Project description:We have identified the CTBP2 protein as a new ZBTB18 interactor. Here we have evaluated transcriptomic changes upon CTBP2 knockdown in the GBM cell line SNB19. Moreover, we have analyzed whether CTBP2 is required for ZBTB18-mediated gene repression.

2019-12-01 | GSE138890 | GEO

MIN6 beta cell CtBP2 ChIP-seq

Project description:CtBP2 ChIP-seq analysis was performed in a murine pancreatic beta cell line MIN6.

2023-08-08 | GSE221257 | GEO

CtBP2 beta cell KO islet RNA-seq

Project description:RNA-seq analysis was performed using pancreatic islet samples from flox mice and beta-cell specific CtBP2 KO mice.

2023-08-08 | GSE221258 | GEO

Genome wide mapping of binding sites of ZBTB18 and CTBP2 in glioblastoma cancer cells

Project description:CTBP2 is a transcriptional co-repressor/co-activator palying a role in EMT. We have identified CTBP2 as a protein interacting with ZBTB18, a transcriptional repressor and tumor suppressor in GBM. Here, we have performed genome wide mapping of CTBP2 and ZBTB18 binding sites in GBM to characterized their gene regulation mechanism.

2022-11-14 | GSE140002 | GEO

C-terminal binding protein (CTBP2) is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma

Project description:Multiple myeloma (MM) cells are addicted to MYC and its direct transactivation target IRF4 for proliferation and survival. MYC and IRF4 are still considered “undruggable” as the majority of small molecule inhibitors suffers from low potency, suboptimal pharmacokinetic properties and undesirable off-target effects. Indirect inhibition of MYC/IRF4 emerges as a therapeutic vulnerability in MM. Here, we uncover an unappreciated tumor suppressive role of C-terminal Binding Protein 2 (CTBP2) in MM via strong inhibition of the MYC-IRF4 axis. In contrast to epithelial cancers, CTBP2 is frequently downregulated in MM, in association with shortened survival, hyperproliferative features and adverse clinical outcomes. Restoration of CTBP2 exhibited potent anti-tumor effects against MM in vitro and in vivo, with marked repression of MYC-IRF4 network genes. Mechanistically, CTBP2 impeded transcription of MYC and IRF4 by histone H3 lysine 27 deacetylation (H3K27ac), and indirectly via activation of MYC repressor IFIT3. In addition, activation of interferon gene signature by CTBP2 suggested its concomitant immunomodulatory role in MM. Epigenetic studies revealed contribution of polycomb-mediated silencing and DNA methylation to CTBP2 inactivation in MM. Notably, inhibitors of Enhance of zeste homolog 2 (EZH2), histone deacetylase (HDACs) and DNA methyltransferase (DNMTs) currently under evaluation in clinical trials were effective in restoring CTBP2 expression in MM. Our findings indicated that loss of CTBP2 plays an essential role in myelomagenesis and decipher an additional mechanistic link on MYC-IRF4 dysregulation in MM. We envision that identification of novel critical regulators would facilitate the development of selective and effective approaches for treating this MYC/IRF4-addicted malignancy.

2024-03-10 | GSE255266 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data